Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma

Head and Neck

Volumn 33, Issue 12, 2011, Pages 1804-1808

  Chung, Christine H ^a,b   Pohlmann, Paula R ^a   Rothenberg, MacE L ^a   Burkey, Brian B ^c   Parker, Joel ^d   Palka, Kevin ^a   Aulino, Joseph ^a   Puzanov, Igor ^a   Murphy, Barbara ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Expression Analysis   (United States)

Author keywords

AMG 479; cetuximab; head and neck squamous cell carcinoma; IGF 1R inhibitor; methotrexate

Indexed keywords

CETUXIMAB; CISPLATIN; DIHYDROFOLATE REDUCTASE; DOCETAXEL; GANITUMAB; IRINOTECAN; METHOTREXATE; SOMATOMEDIN C RECEPTOR;

ADULT; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CASE REPORT; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLOSSECTOMY; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOSPICE CARE; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MUCOSA; NECK DISSECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; METHOTREXATE; MIDDLE AGED; RECEPTOR, IGF TYPE 1;

EID: 81255136527     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21478     Document Type: Article

References (19)

1. Chung CH, Parker JS, Ely K, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006; 66: 8210-8218. (Pubitemid 44299189)
2. Goldman ID, Fyfe MJ,. The mechanism of action of methotrexate. II. Augmentation by vincristine of inhibition of deoxyribonucleic aic synthesis by methotrexate in Ehrlich ascites tumor cells. Mol Pharmacol 1974; 10: 275-282.
3. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24: 4170-4176. (Pubitemid 46622295)
4. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. (Pubitemid 38720929)
5. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042. (Pubitemid 32267973)
6. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712-3718. (Pubitemid 47372612)
7. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-832. (Pubitemid 28280548)
8. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R,. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007; 13: 4291-4299. (Pubitemid 47105993)
9. Slomiany MG, Black LA, Kibbey MM, Tingler MA, Day TA, Rosenzweig SA,. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett 2007; 248: 269-279. (Pubitemid 46330562)
10. Beltran PJ, Mitchell P, Chung YA, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009. [Epub ahead of print]
11. Kuribayashi A, Kataoka K, Kurabayashi T, Miura M,. Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells. Endocrinology 2004; 145: 4976-4984. (Pubitemid 39551115)
12. Gilmore AP, Valentijn AJ, Wang P, et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 2002; 277: 27643-27650. (Pubitemid 34966707)
13. Volpato JP, Fossati E, Pelletier JN,. Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase. J Mol Biol 2007; 373: 599-611. (Pubitemid 47488394)
14. Solit DB, She Y, Lobo J, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2005; 11: 1983-1989. (Pubitemid 40471864)
15. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544. (Pubitemid 46733080)
16. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177. (Pubitemid 46954639)
17. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
18. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
19. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (Pubitemid 32222155)